GFM
DSGN icon

GF Fund Management’s Design Therapeutics DSGN Stock Holding History

GF Fund Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Sell
1,209
-62
-5% -$773 ﹤0.01% 494
2026
Q1 		$13.5K Buy
1,271
+153
+14% +$1.55K ﹤0.01% 535
2025
Q4 		$10.5K Sell
1,118
-95
-8% -$744 ﹤0.01% 570
2025
Q3 		$9.13K Sell
1,213
-236
-16% -$1.18K ﹤0.01% 560
2025
Q2 		$4.88K Hold
1,449
– – ﹤0.01% 628
2025
Q1 		$5.59K Buy
1,449
+260
+22% +$1.24K ﹤0.01% 617
2024
Q4 		$7.34K Buy
+1,189
New +$6.88K ﹤0.01% 581

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's DSGN Position: Q2 2026 in Review

GF Fund Management reduced its Design Therapeutics (DSGN) stake by 4.9% in Q2 2026, selling an estimated $773 and leaving 1,209 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #494.

GF Fund Management first reported a position in DSGN in Q4 2024 and has held it in 7 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • GF Fund Management held 1,209 shares of Design Therapeutics worth $17.5K as of Q2 2026.
  • GF Fund Management sold 62 Design Therapeutics shares in Q2 2026, an estimated $773.
  • Design Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #494 holding.
  • GF Fund Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.